Skip to main content
SpringerLink
Log in
Book cover

L-Dopa-Substitution der Parkinson-Krankheit pp 29–36Cite as

Begleittherapien zu Madopar

  • Chapter

  • 38 Accesses

Zusammenfassung

Pathomorphologische Grundlage des idiopathischen Parkinson-Syndroms ist der progrediente Zelluntergang dopaminerger nigrostriata- 1er Neurone und damit eine Dopaminverarmung der neostriatalen Synapsen (Übersicht siehe [1]). Auch das mesocorticolimbische dopaminerge System [2] und dopaminerge hypothalamische Neurone [3] sind bei der Parkinson-Erkrankung von der Zelldegeneration betroffen. Die Reduktion des cortikalen Noradrenalingehaltes [4] weist auch auf eine Läsion des noradrenergen Systems hin. Seroto- ninerge, cholinerge, gabaerge und peptiderge Systeme sind nur zu einem geringeren Grad von der Erkrankung beeinträchtigt (siehe Übersicht [5]).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seiteiberger, F.: Brain dopamine and the syndromes of Parkinson and Huntington. J. neurol. Sc. 20, 415–455 (1973).

    Article  CAS  Google Scholar 

  2. Javoy-Agid, F., Agid, Y.: Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 30, 1326–1330 (1980).

    PubMed  CAS  Google Scholar 

  3. Javoy-Agid, F., Pique, L., Ruberg M., Ploska, A., Taquet, X., Bertagna, X., Agid, Y: Biochemistry of the hypothalamus in Parkinson”s disease. Neurology 34, 672–675 (1984).

    PubMed  CAS  Google Scholar 

  4. Scatton, B., Javoy-Agid, F, Rouquier, L., Dubois, B., Agid, Y.: Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson”s disease. Brain Res. 275, 321–328 (1983).

    Article  PubMed  CAS  Google Scholar 

  5. Agid, Y.: Biochemische Neuropathologieein neuer Zugang zum Verständnis des Morbus Parkinson. Akt. Neurol. 11, 163–166 (1984).

    Article  Google Scholar 

  6. Birkmayer, W., Hornykiewicz, O.: Der Dioxyphenylalanin-(L-Dopa-) Effekt beim Parkinson-Syndrom des Menschen. Arch. Psych, ges. Neurol. 203, 560–571 (1962).

    CAS  Google Scholar 

  7. Poewe, W., Gerstenbrand, F., Ransmayr, G.: Klinische Manifestationstypen des Parkinson-Syndroms. Neuropsychiatr. Clinica 2, 223–228 (1983).

    Google Scholar 

  8. Marsden, C. D., Foley, Th., Owen, D. A. L., McAllister, R. G.: Peripheral beta-adrenergic receptors concerned with tremor. Clin. Sci. 33, 53–65 (1967).

    PubMed  CAS  Google Scholar 

  9. Gerstenbrand, F., Poewe, W.: Therapeutic efficacy of beta-adrenergic blocking agents in Parkinson tremor. In: Current Concepts in the Treatment of Parkinson”s Disease (Yahr, M., Hrsg.), S. 112–123., Excerpta Medica: 1983.

    Google Scholar 

  10. Gerstenhrand, F., Poewe, W., Stern, G. (Hrsg.).- Clinical Experience with Budipine in Parkinson Therapy. Berlin-Heidelberg-New York-Tokyo: Springer. 1985.

    Google Scholar 

  11. Schwab, R. S.,Poskanzer, D. C.,England, A. C., Young, R. R.: Amantadine in Parkinson”s disease. Review of more than two years experience. J.A.M.A. 222, 792–795 (1972).

    Article  PubMed  CAS  Google Scholar 

  12. Wesemann, W.: Aspekte zum Wirkungsmechanismus von Amantadinen. In: Amantadin-Workshop 1984 (Danielczyk, W., Wesemann, W., Hrsg.), S. 15–23. Gräfelfing: Socio-medico. 1984.

    Google Scholar 

  13. Birkmayer, W., Riederer, P., Ambrozi, L.: Implications of combined treatment with “Madopar” and L-Deprenil in Parkinson”s disease. Lancet 439–443 (1977).

    Google Scholar 

  14. Gerstenbrand, F., Ransmayr, G., Poewe, W.: Deprenyl (selegiline) in combination treatment of Parkinson”s disease. Acta Neurol. Scand., Suppl. 95, 123–126 (1983).

    CAS  Google Scholar 

  15. Marsden, C. D.: Extrapyramidal disorders–new aspects and therapeutic strategies. Introductory guest lecture. 3rd European Workshop on Clinical Neuropharmacology, Rome, April 1985.

    Google Scholar 

  16. Birkmayer, W., Knoll, J., Riederer, P., Youdim, M. B. H.: L-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson”s disease. Mod. Probi. Pharmacopsychiat. 19, 170–176 (1983).

    CAS  Google Scholar 

  17. Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., Petrie, A.: Bromocriptine in parkinsonism. Brit. med. J. 2, 442–444 (1974).

    Article  Google Scholar 

  18. Lees, A.J., Stern, G.M.: Pergolide and lisuride for levodopa-induced oscillations. Lancet ii, 577 (1981).

    Article  Google Scholar 

  19. McDonald, R.J., Llorowski, R.: Lisuride in the treatment of parkinsonism. Eur. Neurolog. 22, 240–255 (1983).

    Article  CAS  Google Scholar 

  20. Poewe, W., Gerstenbrand, F., Ransmayr, G.: Erfahrungen mit dem Dop- aminomimetikum CU 32–085 in der Therapie des Parkinson-Syndroms. Neuropsychiatr. Clin. 1, 117–123 (1982).

    Google Scholar 

  21. Schneider, F., Hubener, K., Fischer, P.A.: Treatment of Parkinson”s disease with 8-alpha-amino-ergoline, CU 32–085. Neurology 33, 468– 472 (1983).

    Google Scholar 

  22. Le Witt, P.A., Ward, C.D., Larsen, T.A., Raphaelson, M.L, Newman, R. P., Foster, N., Dambrosia, J. M., Calne, D. M.: Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 33,1009–1014 (1983).

    CAS  Google Scholar 

  23. Klawans, H. L., Christopher, G. G., Volkman, P., Nausieda, P. A., Weiner, W.J.: Lergotrile in the treatment of parkinsonism. Neurology 28, 699–702 (1978).

    PubMed  CAS  Google Scholar 

  24. Nutt, J. G., Woodward, W. R., Hammerstad, J. P., et al: The on-off phenomenon in Parkinson”s disease: relation to levodopa absorption and transport. N. Engl. J. Med. 310, 483–488 (1984).

    Article  PubMed  CAS  Google Scholar 

  25. Quinn, N., Parkes, D., Marsden, D.: Control of on-off phenomenon by continuous intravenous infusion of levodopa. Neurology 34, 1131–1136 (1984).

    PubMed  CAS  Google Scholar 

  26. Quinn, N., Marsden, C.D., Schachter, M., Thompson, C., Lang, A.E., Parkes,]. D.;Intravenous lisuride in extrapyramidal disorders. In: Lisuride and Other Dopamine Agonists (Calne, D. B., Horowski, R., McDonald, R.J., Wuttke, W., Hrsg.). New York: Raven Press. 1983.

    Google Scholar 

  27. Ogasahara, S., Nishikawa, Y., Takahashi, M., Wada, K., Nakamura, Y., Yorifuji, S., Tarui, S.: Dopamine metabolism in the central nervous system after discontinuation of 1-dopa therapy in patients with parkin- son disease. J. neurol. Sci. 66, 151–163 (1984).

    Article  PubMed  CAS  Google Scholar 

  28. Gerstenbrand, F., Poewe, W., Rainer,].: Neue Entwicklung in der Parkinson-Therapie. Pharmakother. 4, 190–194 (1978).

    Google Scholar 

  29. Ruggieri, S., Denaro, A., Bruno, G., Agnoli, A.: New strategies in the management of Parkinson”s disease: a biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 8, 289– 296 (1982).

    Google Scholar 

  30. Lees, A. J., Stern, G. M.: Sustained bromocriptine therapy in previously untreated patients with Parkinson”s disease. J. Neurol. Neurosurg. Psychiat. 44, 1020–1023 (1981).

    Article  PubMed  CAS  Google Scholar 

  31. Birbamer, G., Ransmayr, G., Poewe, W., Gerstenbrand, F.: Erfahrungen mit einem Apomorphinderivat in der Parkinson-Therapie: Parkinson- Symposium. Wien: Editiones (Roche). 1985. Im Druck.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Universitätsklinik Innsbruck, Anichstraße 35, A-6020, Innsbruck, Österreich

    Prof. Dr. F. Gerstenbrand & G. Ransmayr

Authors
  1. Prof. Dr. F. Gerstenbrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Ransmayr
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ludwig Boltzmann-Institut für klinische Neurobiologie, Krankenhaus der Stadt Wien-Lainz, Österreich

    Peter Riederer

  2. Abteilung Pharma — Marketing, Hoffmann-La Roche Wien Ges. m. b. H., Österreich

    Helga Umek

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Springer-Verlag/Wien

About this chapter

Cite this chapter

Gerstenbrand, F., Ransmayr, G. (1985). Begleittherapien zu Madopar. In: Riederer, P., Umek, H. (eds) L-Dopa-Substitution der Parkinson-Krankheit. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8822-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-8822-4_3

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-8823-1

  • Online ISBN: 978-3-7091-8822-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation